U.S. Chemicals Stock News

In March 2026, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, an oral somatostatin receptor type 2 agonist for adult acromegaly, supported by 18 clinical trials including two Phase 3 studies that met all primary and secondary endpoints and showed favorable tolerability, biochemical control and symptom relief versus placebo. This filing extends PALSONIFY’s regulatory footprint beyond its existing US approval and recent positive CHMP...

In recent days, GLOBALFOUNDRIES Inc. announced past participation at the International Conference on Display Technology 2026 in Chongqing, China, while also disclosing new patent infringement lawsuits against Tower Semiconductor and an insider share sale by Chief Business Officer Michael James Hogan under a Rule 10b5-1 plan. At the same time, a Mubadala Investment Co. unit’s US$840 million secondary share sale, which does not raise capital for GLOBALFOUNDRIES, has sharpened attention on...

Leadership overhaul and fresh management lineup at Aurinia Aurinia Pharmaceuticals (AUPH) has undergone a broad leadership reset, with Kevin Tang becoming Chief Executive Officer, Michael Hearne stepping in as Chief Financial Officer, and Ryan Cole taking on the Chief Operating Officer role. These appointments follow the departure of former CEO Peter Greenleaf and several senior officers. They also bring in multiple executives with ties to Tang Capital Management, a shift that many investors...

Alumis (ALMS) is back in focus after releasing new Phase 3 ONWARD1 and ONWARD2 data on envudeucitinib for moderate to severe plaque psoriasis, alongside plans for a U.S. FDA New Drug Application. See our latest analysis for Alumis. The latest Phase 3 psoriasis data arrives after a sharp run up in Alumis’s 90 day share price return of 181.23%, while the year to date share price return of 160.97% and 1 year total shareholder return of 132.54% point to strong momentum even with a 13.12% 30 day...

Avery Dennison recently reported advances in its RFID and intelligent labeling technologies, aiming to better support global supply chains across multiple industries. This focus on more capable identification solutions underscores how the company is deepening its role in digitizing inventory tracking and materials management worldwide. Next, we’ll explore how Avery Dennison’s enhanced RFID capabilities could influence its investment narrative around intelligent label adoption and...

Piper Sandler analyst Stephen Scouten recently upgraded FB Financial to a buy rating, while keeping his existing US$65 price target unchanged. The upgrade comes from an analyst with a year-long track record of relatively strong success and average returns, which may carry weight with investors assessing FB Financial’s outlook. We’ll now examine how this vote of confidence from a well-regarded analyst interacts with FB Financial’s existing investment narrative and assumptions. Invest in the...

STAG Industrial (STAG) has been drawing attention after recent share performance data showed a 1 day return of 0.94% and a past month return of 4.07% decline, prompting fresh questions about the industrial REIT’s valuation. See our latest analysis for STAG Industrial. At a share price of US$36.55, STAG Industrial’s recent 1 day share price return of 0.94% follows a 30 day share price decline of 4.07%, while its 1 year total shareholder return of 15.90% contrasts with a mildly negative year to...

Revolution Medicines (RVMD) has begun treating patients in RASolute 303, a global Phase 3 trial of its RAS inhibitor daraxonrasib in previously untreated metastatic pancreatic ductal adenocarcinoma, spotlighting a key late stage pipeline milestone. See our latest analysis for Revolution Medicines. That trial milestone comes after a strong run in the stock, with a 90 day share price return of 26.54% and a one year total shareholder return of 216.48%, pointing to strong momentum around the...

Precigen, Inc. has reported full-year 2025 results, with revenue rising to US$9.68 million from US$3.93 million, while net loss widened to US$250.64 million and basic loss per share from continuing operations increased to US$1.37 from US$0.47, ahead of a recent virtual fireside chat with H.C. Wainwright. The combination of sharply higher revenue and a very large year-on-year increase in net loss gives investors new data on how Precigen’s growth efforts are affecting its financial profile. We...

Nomad Foods stock triggered article Nomad Foods (NOMD) has drawn investor attention after a prolonged share price slump, with the stock showing negative returns over the past year and past 3 months. This performance has prompted a closer look at its current fundamentals. See our latest analysis for Nomad Foods. With the latest share price at $9.58, the stock’s 30 day share price return of 6.63% and 90 day share price return of 20.23% point to fading momentum. At the same time, the 1 year...

Event driven snapshot of CVB Financial CVB Financial (CVBF) has recently drawn attention after a period of solid share performance, with the stock showing positive returns over the past week, month, past 3 months, and year to date. See our latest analysis for CVB Financial. The recent positive 7 day and 30 day share price returns, alongside a 1 year total shareholder return of 21.55% and 3 year total shareholder return of 38.61%, suggest momentum has been building around CVB Financial at a...

Reports that the US may apply tariffs of up to 100% on certain imported branded drugs have put regulatory risk front and center for Bristol-Myers Squibb (BMY), prompting investors to reassess the stock. See our latest analysis for Bristol-Myers Squibb. After the tariff headlines and the recent ex dividend adjustment, Bristol Myers Squibb’s 1 day share price return of 3.45% contrasts with a 90 day share price return of 12.33% and a 1 year total shareholder return of 13.16%. This suggests...

In recent weeks, Brinker International has seen a flurry of analyst upgrades and increasingly positive assessments tied to strengthening fundamentals at its Chili’s and Maggiano’s brands. Analysts are pointing to consistent earnings outperformance and improving same-restaurant sales momentum as reasons for a more optimistic view of Brinker's long-term prospects. Next, we’ll explore how this improving Chili’s sales momentum could reshape Brinker International’s existing investment narrative...

Wyndham Hotels & Resorts (WH) is back in focus after its Trademark Collection surpassed 100 U.S. hotels and the company named Amit Sripathi as CFO, alongside broader development leadership changes. See our latest analysis for Wyndham Hotels & Resorts. Those brand milestones and leadership changes come as the share price has recorded a 7.02% 1 month share price return and a 9.15% year to date share price return. The 3 year total shareholder return of 30.11% points to steadier long term...

Honeywell International (HON) has drawn fresh attention after signing a supplier framework agreement with the U.S. Department of War, along with a new AI-focused security collaboration that broadens its exposure to defense and building automation. See our latest analysis for Honeywell International. At a share price of US$229.45, Honeywell has a 90 day share price return of 14.10% and a year to date share price return of 17.14%. The 1 year total shareholder return of 30.25% suggests momentum...

TopBuild Corp. recently promoted Chief Operating Officer John Achille to President and COO, expanding his remit to oversee day‑to‑day operations, supply chain, and all growth initiatives including mergers and acquisitions across its Installation Services and Specialty Distribution businesses. This leadership change elevates an executive with deep internal experience and M&A responsibility at a time when acquisitions are a key pillar of TopBuild’s growth approach. With John Achille now...

Why Dyne Therapeutics is on investors’ radar today Dyne Therapeutics (DYN) has drawn attention after recent trading, with the stock closing at US$18.84 and posting a 26.8% return over the past month. This performance has prompted closer scrutiny of its risk reward profile. See our latest analysis for Dyne Therapeutics. Recent trading strength, including a 9.9% 7 day share price return and a 26.8% 30 day share price return, sits alongside a 127.5% 1 year total shareholder return. This...

Analysts recently increased full-year earnings projections for China Yuchai International (CYD) by 40.5%, and the stock has outperformed both its Auto Tires Trucks sector and the Automotive Original Equipment industry so far this year. See our latest analysis for China Yuchai International. The current share price of US$39.41 comes after a mixed stretch, with a 7 day share price return of 5.66% and a 30 day share price decline of 4.58%, while the 1 year total shareholder return of 181.62% and...

In late March 2026, Braze reported fourth-quarter and full-year results showing higher sales but continued net losses, issued new revenue guidance for fiscal 2027, filed a US$121.93 million shelf registration tied to an ESOP-related Class A share offering, and authorized a US$100 million share repurchase program. On April 2, 2026, Wunderkind announced a new integration with Braze that links its identity and behavioral Signals directly into Braze Canvas, aiming to help brands recognize more...

Why Hologic (HOLX) is on investors’ radar today Hologic (HOLX) has drawn investor interest recently as its share price, which last closed at US$75.65, reflects mixed short term performance and a moderate gain over the past 3 months. Over the past month, Hologic’s return was roughly flat, while the past 3 months show a gain of about 1%. Over the past year, the stock’s total return of about 24% contrasts with a slight negative total return over 3 years and a modest gain over 5 years. These...

Ubiquiti (UI) has drawn fresh attention after a sharp intraday move, with the stock breaking above key moving averages and the upper Bollinger Band as several momentum indicators pointed to strong technical strength. See our latest analysis for Ubiquiti. The latest breakout builds on a strong run, with a 90 day share price return of 49.02% and a 1 year total shareholder return of 209.19%, so momentum currently appears to favor existing holders. If this kind of move has you thinking about what...

Liberty Live Holdings (LLYV.K) has drawn fresh attention after recent share price moves, with the stock last closing at $97. This puts the company’s market value at about $8.9b in live entertainment. See our latest analysis for Liberty Live Holdings. For context, Liberty Live Holdings has seen a 1-day share price return of 2.28% and a 7-day share price return of 9.37%. The 1-year total shareholder return sits at 50.71%, which indicates that momentum has been building rather than fading. If...

In late March 2026, NVIDIA and Marvell Technology announced an expanded partnership, including a US$2.00 billion NVIDIA investment and integration of Marvell’s custom XPUs and networking with NVIDIA’s NVLink Fusion platform to build next-generation AI data centers and AI-RAN telecom infrastructure. This move extends NVIDIA’s role beyond GPUs into co-designed networking, silicon photonics, and carrier-grade systems, tightening its grip on the broader AI infrastructure stack that underpins...

Why Clearway Energy Is On Investors’ Radar Clearway Energy (CWEN.A) has drawn attention after its recent share price performance, with the stock showing positive returns over the past week, month, past 3 months, and year. For investors tracking clean energy names, that kind of consistency invites a closer look at what is driving sentiment around Clearway’s business, cash flows, and long term portfolio of wind, solar, storage, and flexible generation assets. See our latest analysis for...